Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months

Core Insights - Aurion Biotech announced positive 12-month results from its Phase 1/2 CLARA trial, which assessed the safety, efficacy, and tolerability of AURN001 in patients with corneal edema due to corneal endothelial dysfunction [1] Company Summary - Aurion Biotech is a clinical-stage regenerative medicine company focused on restoring vision for millions of patients [1] - The trial evaluated AURN001, which consists of human corneal endothelial cells combined with Y-27632 rho-kinase inhibitor [1]